1. Home
  2. INSM vs EWBC Comparison

INSM vs EWBC Comparison

Compare INSM & EWBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INSM
  • EWBC
  • Stock Information
  • Founded
  • INSM 1988
  • EWBC 1998
  • Country
  • INSM United States
  • EWBC United States
  • Employees
  • INSM N/A
  • EWBC N/A
  • Industry
  • INSM Biotechnology: Pharmaceutical Preparations
  • EWBC Major Banks
  • Sector
  • INSM Health Care
  • EWBC Finance
  • Exchange
  • INSM Nasdaq
  • EWBC Nasdaq
  • Market Cap
  • INSM 14.3B
  • EWBC 13.6B
  • IPO Year
  • INSM 2000
  • EWBC 1999
  • Fundamental
  • Price
  • INSM $81.06
  • EWBC $93.89
  • Analyst Decision
  • INSM Strong Buy
  • EWBC Strong Buy
  • Analyst Count
  • INSM 15
  • EWBC 13
  • Target Price
  • INSM $92.00
  • EWBC $110.38
  • AVG Volume (30 Days)
  • INSM 1.8M
  • EWBC 853.0K
  • Earning Date
  • INSM 02-20-2025
  • EWBC 01-23-2025
  • Dividend Yield
  • INSM N/A
  • EWBC 2.56%
  • EPS Growth
  • INSM N/A
  • EWBC 1.83
  • EPS
  • INSM N/A
  • EWBC 8.33
  • Revenue
  • INSM $363,707,000.00
  • EWBC $2,385,692,000.00
  • Revenue This Year
  • INSM $20.03
  • EWBC N/A
  • Revenue Next Year
  • INSM $41.61
  • EWBC $7.41
  • P/E Ratio
  • INSM N/A
  • EWBC $11.27
  • Revenue Growth
  • INSM 19.17
  • EWBC 0.99
  • 52 Week Low
  • INSM $21.92
  • EWBC $68.78
  • 52 Week High
  • INSM $84.87
  • EWBC $113.95
  • Technical
  • Relative Strength Index (RSI)
  • INSM 58.18
  • EWBC 34.49
  • Support Level
  • INSM $79.50
  • EWBC $96.54
  • Resistance Level
  • INSM $80.28
  • EWBC $99.48
  • Average True Range (ATR)
  • INSM 2.98
  • EWBC 2.11
  • MACD
  • INSM 0.06
  • EWBC -0.63
  • Stochastic Oscillator
  • INSM 63.38
  • EWBC 1.15

About INSM Insmed Incorporated

Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.

About EWBC East West Bancorp Inc.

East West Bancorp Inc is the holding company for East West Bank, a full-service commercial bank with cross-border operations concentrated in the United States and China. East-West Bank is one of a few U.S. based banks with a full banking license in China. The bank's cost strategy has increasingly focused on expanding its deposit base away from time deposits to commercial deposits. The bank has also taken part in entertainment partnerships between participants in China and Hollywood. Most of these efforts include financing the production and distribution of film and television projects. The bank leverages its cultural and regulatory knowledge in the U.S. and China to assist its customers in entering new markets. Most of its earning assets are in loans held for investment.

Share on Social Networks: